Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients

European Journal of Surgical Oncology

Volumn 35, Issue 8, 2009, Pages 805-813

  Langer, I ^a   Guller, U ^a   Hsu Schmitz, S F ^b   Ladewig, A ^a   Viehl, C T ^a   Moch, H ^c   Wight, E ^a   Harder, F ^a   Oertli, D ^a   Zuber, M ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Kantonsspital Olten ^*  (Switzerland)

Author keywords

Axillary dissection; Breast cancer; Disease free and overall survival; Long term follow up; Sentinel lymph node

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS;

EID: 67649271488     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.09.006     Document Type: Article

References (43)

1. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
2. McMasters K.M., Tuttle T.M., Carlson D.J., et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18 (2000) 2560-2566
3. Giuliano A.E., Dale P.S., Turner R.R., Morton D.L., Evans S.W., and Krasne D.L. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222 (1995) 394-399
4. Giuliano A.E., Barth A.M., Spivack B., Beitsch P.D., and Evans S.W. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 183 (1996) 185-189
5. Giuliano A.E., Jones R.C., Brennan M., and Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15 (1997) 2345-2350
6. Hill A.D., Tran K.N., Akhurst T., et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 229 (1999) 528-535
7. Reynolds C., Mick R., Donohue J.H., et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?. J Clin Oncol 17 (1999) 1720-1726
8. Turner R.R., Chu K.U., Qi K., et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89 (2000) 574-581
9. Veronesi U., Paganelli G., Viale G., et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 91 (1999) 368-373
10. Veronesi U., Galimberti V., Zurrida S., et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 37 (2001) 454-458
11. Weaver D.L., Krag D.N., Ashikaga T., Harlow S.P., and O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 88 (2000) 1099-1107
12. Dowlatshahi K., Fan M., Snider H.C., and Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 80 (1997) 1188-1197
13. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18 (2000) 2553-2559
14. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349 (2003) 546-553
15. Langer I., Marti W.R., Guller U., et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241 (2005) 152-158
16. Purushotham A.D., Upponi S., Klevesath M.B., et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23 (2005) 4312-4321
17. Carlo J.T., Grant M.D., Knox S.M., et al. Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer. Proc (Bayl Univ Med Cent) 18 (2005) 103-107
18. Veronesi U., Galimberti V., Mariani L., et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 41 (2005) 231-237
19. Berg J.W. The significance of axillary node levels in the study of breast carcinoma. Cancer 8 (1955) 776-778
20. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
21. Goldhirsch A., Wood W.C., Senn H.J., Glick J.H., and Gelber R.D. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87 (1995) 1441-1445
22. Goldhirsch A., Glick J.H., Gelber R.D., and Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90 (1998) 1601-1608
23. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., and Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19 (2001) 3817-3827
24. Langer I., Guller U., Berclaz G., et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 245 (2007) 452-461
25. Fisher B., Redmond C., Fisher E.R., et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312 (1985) 674-681
26. Fredriksson I., Liljegren G., Arnesson L.G., et al. Consequences of axillary recurrence after conservative breast surgery. Br J Surg 89 (2002) 902-908
27. Ivens D., Hoe A.L., Podd T.J., Hamilton C.R., Taylor I., and Royle G.T. Assessment of morbidity from complete axillary dissection. Br J Cancer 66 (1992) 136-138
28. Harris J.R., and Osteen R.T. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 5 (1985) 17-21
29. Harder L., and Harder F. Outcome and complications after standard axillary lymph node dissection in breast cancer. Thesis (2002), University of Basel, Switzerland
30. Winchester D.J., Menck H.R., and Winchester D.P. The National Cancer Database report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer 80 (1997) 162-167
31. Fisher B., Dignam J., Tan-Chiu E., et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93 (2001) 112-120
32. van Dongen J.A., Voogd A.C., Fentiman I.S., et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial. J Natl Cancer Inst 92 (2000) 1143-1150
33. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
34. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
35. Tan L.K., Giri D., Hummer A.J., et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 26 (2008) 1803-1809
36. Haid A., Knauer M., Koberle-Wuhrer R., et al. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol 32 (2006) 1180-1185
37. Torrenga H., Fabry H., van dS Jr., van Diest P.J., Pijpers R., and Meijer S. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long-term follow-up analysis. J Surg Oncol 88 (2004) 4-7
38. de Kanter A.Y., Menke-Pluymers M.M., Wouters M.W., Burgmans I., van Geel A.N., and Eggermont A.M. Five-year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 32 (2006) 282-286
39. Fuhrman G.M., Gambino J., Bolton J.S., Farr G., and Jiang X. Five-year follow-up after sentinel node mapping for breast cancer demonstrates better than expected treatment outcomes. Am Surg 71 (2005) 564-569
40. Chu K.U., Turner R.R., Hansen N.M., Brennan M.B., and Giuliano A.E. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 6 (1999) 756-761
41. Cox C., White L., Allred N., et al. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol 13 (2006) 708-711
42. Kuijt G.P., van de Poll-Franse L.V., Voogd A.C., Nieuwenhuijzen G.A., and Roumen R.M. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 33 (2007) 832-837
43. Turner R.R., Ollila D.W., Stern S., and Giuliano A.E. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol 23 (1999) 263-267